Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

View Full Paper
Ask AI
Bookmark
Share

Authors

DLDanyang LiZFZhonghua FuFYFan Yang

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows CAR-T therapy improves treatment outcomes for CNS lymphoma with TP53 mutations, suggesting new therapeutic approaches.

Key Points

  • To assess the efficacy and safety of CAR-T therapy in CNS lymphoma patients with TP53 mutations.
  • Conducted a retrospective cohort study including 61 CNSL patients treated from 2020 to 2024.
  • Evaluated overall response rate, complete response rate, overall survival, progression-free survival, and adverse events.
  • Used Kaplan-Meier survival curves and log-rank tests for statistical analysis, focusing on TP53 mutation status.
  • TP53 mutations were present in 21 of the 61 patients studied.
  • The overall response rate for TP53+CAR-T+ was 64.5% and for TP53-CAR-T+ was 73.3%.
  • Median PFS was 20.17 months for TP53+ compared to 24.07 months for TP53- group.
  • Statistical analysis revealed no significant differences in treatment efficacy between CAR-T and non-CAR-T groups.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236dec4https://doi.org/10.1182/blood-2025-3708
View Full Paper
Ask AI
Bookmark
Share